Texas journaly 2 trial#
Texas journaly 2 license#

In the initial 31 days of the vaccination campaign, 59% of 23,234 UTSW employees received a first dose of either one of the mRNA vaccines and 30% received a second dose. The actual number of positive tests (black dots) decreased from January 9 (blue line) onward (25 days after the initiation of employee vaccinations). The shaded area denotes the 95% confidence interval. Panel B shows that the number of positive tests was projected to increase without vaccination (black line). Nonvaccinated persons were those for whom there was no record of vaccine received at UTSW, partially vaccinated persons were those who had received one dose or who had received the second dose of the BNT162b2 vaccine less than 7 days before the index date or the second dose of the mRNA-1273 vaccine less than 14 days before the index date, and fully vaccinated persons were those who had received the second dose of the BNT162b2 vaccine at least 7 days before the index date or the second dose of the mRNA-1273 vaccine at least 14 days before the index date. Vaccination status was determined at the time of the first SARS-CoV-2–positive test on or after December 15 if no infection was detected between December 15 and January 28, the vaccination status on January 28 was used. Panel A shows the percentage of persons with new SARS-CoV-2 infection among 23,234 employees of the University of Texas Southwestern Medical Center (UTSW) who were eligible to receive SARS-CoV-2 vaccine, stratified according to vaccination status from December 15, 2020, through January 28, 2021. This escalation led to the largest surge to date in the region and strained health systems. The launch of the vaccination effort coincided with a rapidly escalating number of new SARS-CoV-2 infections in North Texas. Here, we report data from the University of Texas Southwestern Medical Center (UTSW), which initiated a program on December 15, 2020, to offer vaccine against SARS-CoV-2 to its frontline employees in phase 1a of vaccination, as directed by the Texas Department of State Health Services. These Food and Drug Administration actions were based on impressive results of clinical trials, but only in the weeks since the authorizations has real-world evidence been available to shed light on the overall effect of the vaccines on transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and related illness. The most trusted, influential source of new medical knowledge and clinical best practices in the world.Įffectiveness of Covid-19 Vaccination in Health Care Workers at Four InstitutionsĮmergency use authorizations for two messenger RNA (mRNA) vaccines - the BNT162b2 vaccine (Pfizer–BioNTech) and the mRNA-1273 vaccine (Moderna) - marked important milestones in efforts to respond to the coronavirus disease 2019 (Covid-19) pandemic.

Texas journaly 2 license#

Information and tools for librarians about site license offerings. Valuable tools for building a rewarding career in health care. The authorized source of trusted medical research and education for the Chinese-language medical community. The most advanced way to teach, practice, and assess clinical reasoning skills. Information, resources, and support needed to approach rotations - and life as a resident. The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams.

NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Ĭoncise summaries and expert physician commentary that busy clinicians need to enhance patient care.

Texas journaly 2 trial#

NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.